Published in PLoS One on September 13, 2011
Fluphenazine reduces proteotoxicity in C. elegans and mammalian models of alpha-1-antitrypsin deficiency. PLoS One (2014) 0.88
Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proc Natl Acad Sci U S A (2014) 0.85
A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. ACS Med Chem Lett (2012) 0.79
Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion protein. Nat Commun (2016) 0.75
Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med (2001) 4.75
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A (2001) 3.39
Molecular mechanisms of prion pathogenesis. Annu Rev Pathol (2008) 3.05
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
A systematic review of prion therapeutics in experimental models. Brain (2006) 2.25
New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol (2003) 2.09
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Prion diseases and their biochemical mechanisms. Biochemistry (2009) 1.65
Evaluation of quinacrine treatment for prion diseases. J Virol (2003) 1.59
Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist. Neurology (2008) 1.54
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
A prion disease of cervids: chronic wasting disease. Vet Res (2008) 1.46
Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol (2002) 1.46
Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol (1995) 1.42
Susceptibilities of nonhuman primates to chronic wasting disease. Emerg Infect Dis (2009) 1.33
Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J Virol (2005) 1.33
Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol (2007) 1.26
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol (2007) 1.06
Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis (2009) 1.00
High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience (2008) 0.98
Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies. J Neurochem (2006) 0.91
Astrocytosis and amyloid deposition in scrapie-infected hamsters. Brain Res (1998) 0.89
Prions and protein-folding diseases. J Intern Med (2011) 0.89
Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques. Chembiochem (2007) 0.89
Immunotherapy for prion diseases: opportunities and obstacles. Immunotherapy (2010) 0.89
New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels. Science (2003) 0.84
Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines (2010) 0.80
Psychotropic medications and the treatment of human prion diseases. CNS Neurol Disord Drug Targets (2009) 0.79
Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung (2004) 0.79
Therapeutic interventions ameliorating prion disease. Expert Rev Anti Infect Ther (2009) 0.78
Mechanistic insights into the cure of prion disease by novel antiprion compounds. J Virol (2007) 0.77
A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J (2002) 3.87
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Nuclear envelope budding enables large ribonucleoprotein particle export during synaptic Wnt signaling. Cell (2012) 3.50
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 2.83
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol (2010) 2.42
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem Biol (2006) 2.09
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 2.00
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J (2007) 1.97
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Identification of a novel protein regulating microtubule stability through a chemical approach. Chem Biol (2004) 1.64
RNA-selective, live cell imaging probes for studying nuclear structure and function. Chem Biol (2006) 1.63
A single-cell analysis of myogenic dedifferentiation induced by small molecules. Chem Biol (2005) 1.63
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Dissection of melanogenesis with small molecules identifies prohibitin as a regulator. Chem Biol (2005) 1.48
Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus. Blood (2010) 1.47
Novel orthogonal strategy toward solid-phase synthesis of 1,3,5-substituted triazines. Org Lett (2003) 1.46
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem (2007) 1.44
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci (2004) 1.43
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
Triazine-based tyrosinase inhibitors identified by chemical genetic screening. Pigment Cell Res (2005) 1.40
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
Chemical genetics. Chem Rev (2006) 1.37
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
Combinatorial strategies in fluorescent probe development. Chem Rev (2012) 1.28
Immunization delays the onset of prion disease in mice. Am J Pathol (2002) 1.26
Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J Biol Chem (2004) 1.26
Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis (2002) 1.24
Bioactive small molecules reveal antagonism between the integrated stress response and sterol-regulated gene expression. Cell Metab (2005) 1.23
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
Small molecule microarrays: recent advances and applications. Curr Opin Chem Biol (2005) 1.22
Forward chemical genetic approach identifies new role for GAPDH in insulin signaling. Nat Chem Biol (2006) 1.19
Ultrasensitive near-infrared Raman reporters for SERS-based in vivo cancer detection. Angew Chem Int Ed Engl (2011) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Copper chelation delays the onset of prion disease. J Biol Chem (2003) 1.17
Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (2007) 1.15
Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res (2004) 1.11
Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis (2001) 1.11
Identification of a new class of prostaglandin transporter inhibitors and characterization of their biological effects on prostaglandin E2 transport. J Pharmacol Exp Ther (2005) 1.10
Surface-enhanced Raman scattering in cancer detection and imaging. Trends Biotechnol (2013) 1.09
Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett (2003) 1.09
Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res (2004) 1.08
Facilitated forward chemical genetics using a tagged triazine library and zebrafish embryo screening. J Am Chem Soc (2003) 1.07
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol (2002) 1.07
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem (2003) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol (2007) 1.06
Combinatorial rosamine library and application to in vivo glutathione probe. J Am Chem Soc (2007) 1.06
A chemical screen identifies novel compounds that overcome glial-mediated inhibition of neuronal regeneration. J Neurosci (2010) 1.05
Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility. Protein Sci (2009) 1.03
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol (2012) 1.02
Development of photostable near-infrared cyanine dyes. Chem Commun (Camb) (2010) 1.01
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol (2006) 1.01
A fluorescent rosamine compound selectively stains pluripotent stem cells. Angew Chem Int Ed Engl (2010) 1.01
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol (2004) 1.01
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol (2008) 1.00
Colorimetric identification of carbohydrates by a pH indicator/pH change inducer ensemble. Angew Chem Int Ed Engl (2006) 1.00
Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis (2009) 1.00
Multiplex cancer cell detection by SERS nanotags with cyanine and triphenylmethine Raman reporters. Chem Commun (Camb) (2011) 0.99
Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice. J Virol (2008) 0.99
A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening. Mol Biosyst (2012) 0.99
Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage (2011) 0.98
Tools for target identification and validation. Curr Opin Chem Biol (2004) 0.98
Novel use of fluorescent glucose analogues to identify a new class of triazine-based insulin mimetics possessing useful secondary effects. Mol Biosyst (2010) 0.98
Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry (2005) 0.97
Diversity-oriented optical imaging probe development. Curr Opin Chem Biol (2011) 0.96
Embryonic and induced pluripotent stem cell staining and sorting with the live-cell fluorescence imaging probe CDy1. Nat Protoc (2011) 0.96
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol (2013) 0.96
Intracellular glutathione detection using MnO(2)-nanosheet-modified upconversion nanoparticles. J Am Chem Soc (2011) 0.95
Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. J Virol (2005) 0.95
Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors. Antiviral Res (2012) 0.95
Combinatorial approach to organelle-targeted fluorescent library based on the styryl scaffold. J Am Chem Soc (2003) 0.95
Rapid identification of immunostimulatory alpha-galactosylceramides using synthetic combinatorial libraries. J Comb Chem (2007) 0.95
Synthesis and anticancer activity studies of cyclopamine derivatives. Bioorg Med Chem Lett (2008) 0.95
Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis (2011) 0.94
Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment. Biochem Biophys Res Commun (2003) 0.94
Development of biocompatible SERS nanotag with increased stability by chemisorption of reporter molecule for in vivo cancer detection. Biosens Bioelectron (2010) 0.94
Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol (2004) 0.94
Infectivity of amyloid diseases. Trends Mol Med (2002) 0.93
Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. Int J Alzheimers Dis (2012) 0.93
Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One (2010) 0.93
Microarrays of tagged combinatorial triazine libraries in the discovery of small-molecule ligands of human IgG. J Comb Chem (2004) 0.93
A novel microtubule destabilizing entity from orthogonal synthesis of triazine library and zebrafish embryo screening. J Am Chem Soc (2002) 0.93